Although the inhibition to inhibitory T cell receptors such as programmed cell death protein 1 (PD-1) and its ligand PD-L1 can induce anti-tumor T cell responses, most of tumor patients shown response to single-drug therapy by ICI at a low rate (20%–40%) (Rodriguez-Pascual et al., 2019). Here, PDCD1 is linked to neoplasm.